What's new in atopic eczema?

Bibliography

• In: Ring J, Przybilla B, Ruzicka T, editors. Handbook of atopic eczema. 2nd edition. Springer Berlin, Heidelberg, New York; 2006
   Google Scholar
• Leung DY. Atopic eczema: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-76
   PubMed Web of Science ®Google Scholar
• Ring J. Atopy: condition, disease or syndrome? In: Ring J, Przybilla B, Ruzicka T, editors, Handbook of atopic eczema. Springer, Berlin, Heidelberg, New York; 2006. p. 3
   Google Scholar
• Wise F, Sulzberger MB. Footnote on problem of eczema, neurodermatitis and lichenification. In: Wise F, Sulzberger MB, editors, The 1933 year book of dermatology and syphilology. Year book publishers, Chicago; 1933. p. 38-39
   Google Scholar
• Hanifin JM, Rajka. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-7
   Google Scholar
• Williams HC, Burney PG, Pembroke AC, Hay RJ. The UK Working Party's Diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994;131(3):397-405
   PubMed Web of Science ®Google Scholar
• Bos JD, van Leent EJ, Sillevis Smitt JH. The millennium criteria for the diagnosis of atopic eczema. Exp Dermatol 1998;7:132-8
   PubMed Web of Science ®Google Scholar
• Darsow U, Vieluf D, Ring J. The atopy patch test: an increased rate of reactivity in patients who have an airexposed pattern of atopic eczema. Br J Dermatol 1996;135:182-6
   PubMed Web of Science ®Google Scholar
• Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitation in atopic ezcema with the atopy patch test: a randomized, double-blind multicenter study. J Am Acad Dermatol 1999;40:187-93
   PubMed Web of Science ®Google Scholar
• Wüthrich B. Definition and diagnosis of intrinsic versus extrinsic atopic dermatitis. In: Bieber T, Leung DYM, editors, Atopic dermatitis. Marcel Decker, New York; 2002. p. 1-20
   Google Scholar
• Kekki OM, Turjanmaa K, Isolauri E. Differences in skin-prick and patch-test reactivity are related to the heterogeneity of atopic eczema in infants. Allergy 1997;52:755-9
   PubMed Web of Science ®Google Scholar
• Ring J, Kramer U, Schafer T, Behrendt H. Why are allergies increasing? Curr Opin Immunol 2001;13:701-8
   PubMed Web of Science ®Google Scholar
• Williams HC, Strachan DP, Hay RJ. Childhood eczema: disease of the advantaged? Br Med 1994;308:1132-5
   PubMed Web of Science ®Google Scholar
• Strachan DP. Hay fever, hygiene and household size. Br Med 1989;299:1259-60
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Enomot T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh M, Kremser PG, van Ree R. Allergy, parasites and the hygiene hypothesis. Science 2002;296:490-4
   PubMed Web of Science ®Google Scholar
• Kramer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy in later childhood. Lancet 1999;353:450-4
   PubMed Web of Science ®Google Scholar
• Riedler J, Braun-Fahrlander C, Eder W, Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;358:1129-33
   PubMed Web of Science ®Google Scholar
• Matricardi PM, Bonini S. High microbial turnover rate preventing atopy: a solution to inconsistencies impinging on the hygiene hypothesis? Clin Exp Allergy 2000;30(11):1506-10
   PubMed Web of Science ®Google Scholar
• Schäfer T, Krämer U, Behrendt H, Ring J. Epidemiologie des atopischen Ekzems. Allergo J 2003;12:430-8
   Google Scholar
• Eales LJ. Cells and tissues for the immune system. Immunology for life scientists. Eals edt. Wiley, Chichester; 2003. p. 1-28
   Google Scholar
• Bieber T, de la Salle C, Wollenberg A, Constitutive expression of the high affinity receptor for IgE (FcepsilonRa) on human Langerhans cells. J Exp Med 1992;175:1285-90
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Wen S, Bieber T. Langerhans'cells phenotyping: a new tool for differential diagnosis of inflammatory skin diseases. Lancet 1997;346:1626-7
   Web of Science ®Google Scholar
• Akdis M, Trautmann A, Blaser K, Akdis C. T cells and effector mechanisms in the pathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2002;2:1-3
   PubMedGoogle Scholar
• Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic eczema. J Am Acad Dermatol 2005;53:171-6
   PubMed Web of Science ®Google Scholar
• Novak N. New insights into the mechanism and management of allergic diseases: atopic eczema. Allergy 2009;64:265-75
   PubMed Web of Science ®Google Scholar
• Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006;118:178-89
   PubMed Web of Science ®Google Scholar
• Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in Atopic eczema: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008;121:1337-43
   PubMed Web of Science ®Google Scholar
• Proksch E, Fölster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006;43:159-69
   PubMed Web of Science ®Google Scholar
• Weidinger S, Illig T, Baurecht H, Loss-of-function variations within the filaggrin gene predispose for atopic eczema with allergic sensitations. J Allergy Clin Immunol 2006;118:214-9
   PubMed Web of Science ®Google Scholar
• Jensen JM, Fölster-Holst R, Proksch E. Impaired barrier function and the pathogenesis of atopic eczema. G Ital Dermatol Venerol 2007;142:639-48
   Google Scholar
• Baker BS. The role of microorganisms in Atopic eczema. Clin Exp Immunol 2006;144:1-9
   PubMed Web of Science ®Google Scholar
• Weidinger S, Rodriguez E, Stahl C, Filaggrin mutations strongly predispose to early-onset and extrinsic Atopic eczema. J Invest Dermatol 2007;127:724-6
   PubMed Web of Science ®Google Scholar
• Weidinger S, O´Sullivan M, Illig T, Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008;121:1203-9
   PubMed Web of Science ®Google Scholar
• Elias P, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic eczema. Curr Allergy Asthma Rep 2008;4:1534-6315
   Google Scholar
• Lubbe J. Secondary infections in patients with Atopic eczema. Am J Clin Dermatol 2003;4:641-54
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Bzowska M, Kasprowicz A, Persistent skin colonization with Staphylococcus aureus in Atopic eczema: relationship to clinical and immunogical parameters. Clin Exp Allergy 2005;35:448-55
   PubMed Web of Science ®Google Scholar
• Breuer K, Werfel T, Kapp A. Staphylococcal exotoxins as trigger factors of atopic eczema. In: Ring J, Behrend H, editors, New trends in allergy V. Springer, Berlin, Heidelberg, New York; 2002. p. 145-56
   Google Scholar
• Ong PY, Ohtake T, Brandt C, Endogenous antimicrobial peptides and skin infections in atopic eczema. N Eng J Med 2002;347:1151-60
   PubMed Web of Science ®Google Scholar
• De Benedetto A, Agnithothri R, McGirt LY, Atopic eczema: a disease caused by innate immune defects? J Invest Dermatol 2009;129:14-30
   PubMed Web of Science ®Google Scholar
• Darsow U, Wollenberg A, Simon D, ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic eczema. J Eur Acad Dermatol Venerol 2009. [Epub ahead of print]
   Google Scholar
• Grimalt R, Mengeaud V, Cambazard F, Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007;214(1):61-7
   PubMed Web of Science ®Google Scholar
• Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venerol 2006;54:821
   Google Scholar
• Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30(10):861-81
   PubMed Web of Science ®Google Scholar
• Kansky A, Podrumac B, Godic A. Nonfluorinated corticosteroid topical preparations in children. Acta Dermatovenerol Alp Panonica Adriat 2000;9(2):67-72
   Google Scholar
• Thomson KF, Wilkinson SM, Powell S, Beck MH. The prevalence of corticosteroid allergy in two U.K. centres: prescribing implications. Br J Dermatol 1999;141(5):863-6
   PubMed Web of Science ®Google Scholar
• Hoetzenecker W, Ecker R, Stingl G, Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic eczema. J Allergy Clin Immunol 2005;115:1276-83
   PubMed Web of Science ®Google Scholar
• Ring J, Abraham A, de Cuyper C, Control of atopic eczema with pimecrolimus cream 1 % in pediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008;22:718-21
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Bieber T, Schöpf E, A short-term trial of tacrolimus ointment for atopic eczema. N Eng J Med 1997;337:816-21
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M, Efficacy and safety of pimecrolimus cream in the long-term management of atopic eczema in children. Pediatrics 2002;110(1 Pt 1):e2
   PubMed Web of Science ®Google Scholar
• Reitamo S, Wollenberg A, Schöpf E, Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic eczema. Arch Dermatol 2000;136:999-1006
   PubMed Web of Science ®Google Scholar
• Meurer M, Fölster-Holst R, Wozel G, Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-7
   PubMed Web of Science ®Google Scholar
• Bieber T, Cork M, Ellis C, Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005;211:77-8
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Pediatric Advisory Committee. February 15, 2005; Briefing information. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm
   Google Scholar
• Kalthoff Fs, Chung J, Stuetz A. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activarion by allogenieic dendritic cells. Clin Exp Immunol 2002;130:85-2
   PubMed Web of Science ®Google Scholar
• Jensen JM, Pfeiffer S, Witt M, Different effects of pimecrolimus and bethamethasone on the skin barrier in patients with atopic eczema. J Allergy Clin Immunol 2009;14(3 Suppl 2):R19-28
   Web of Science ®Google Scholar
• Mihm MC, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67:305-12
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Wen S, Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999;37:147-55
   PubMedGoogle Scholar
• Wollenberg A, Reitamo S, Girolomonoi G, Proactive treatment of atopic eczema in adults with 0,1 % tracrolimus ointment. Allergy 2008;63:742-50
   Web of Science ®Google Scholar
• Wollenberg A, Bieber T. Proactive therapy of atopic eczema – an emerging concept. Allergy 2009;64:276-8
   PubMed Web of Science ®Google Scholar
• Kowalzick L. Kleinheinz A. Weichenthal M, Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol 1995;75(1):43-5
   PubMed Web of Science ®Google Scholar
• Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000;25(7):552-8
   PubMed Web of Science ®Google Scholar
• Hong SP, Kim MJ, Jung MY, Biopositive effects of low dose UVB on epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. J Invest Dermatol 2008;128(12):2880-7
   PubMed Web of Science ®Google Scholar
• Gläser R, Navid F, Schuller W, UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo. J Allergy Clin Immunol 2009;123(5):117-1123
   Google Scholar
• Schwarz T. The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisted. J Invest Dermatol 2009;130:49-54
   Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191
   PubMedGoogle Scholar
• Klein PA, Clark RA. An evidence-based review on the efficacy of antihistamines in relieving pruritus in atopic dermatits. Arch Dermatol 1999;135:1522-5
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Cooper KD, Ho VC, Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol 2004;50(3):391-404
   PubMed Web of Science ®Google Scholar
• Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic eczema and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189-98
   PubMed Web of Science ®Google Scholar
• Brockow K, Grabenhorst P, Abeck D, Effect of gentian violet, corticosteroid and tar preparations in staphylococcus-aureus- colonized atopic eczema. Dermatology 1999;199(3):231-6
   PubMed Web of Science ®Google Scholar
• Parish LC, Jorizzo JL, Breton JJ, Topical retapamulin ointment (1%) twice daily for 5 days versus oral cephalexin twice dialy for 10 days in the treatement of secondarily infected dermatitis. Results of a randomized controlled trial. Pediatr Allergy Immunol 2007;18(4):335-8
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Sampson H, Leung SB, Effects of cefuroxime on staphylococcus aureus colonization and superantighen production in atopic dermatitis. J Allergy Clin Immunol 2001;108(4);651-652
   PubMed Web of Science ®Google Scholar
• Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001;56(11):1034-1041
   PubMed Web of Science ®Google Scholar
• Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to recuce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008;(E):CD003871
   Google Scholar
• Mayser P, Kupfer J, Nemetz D, Treatment of head and neck dermatitis with ciclopiroxolamine cream – results of a double-blind, placebo controlled study. Skin Pharmacol Physiol 2006;19(3):153-9
   PubMed Web of Science ®Google Scholar
• Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic eczema with IgE-mediated hypersensivity to yeasts. Allergy 2001;144(4):512-7
   Web of Science ®Google Scholar
• Gauger A, Fischer S, Mempel M, Efficacy and functionality of silver-coated textiles in patients with atopic eczema. J Eur Acad Dermatol Venereol 2006;20(5):534-41. Erratum appears in J Eur Acad Dermatol Venereol 2006;20(6):771
   PubMed Web of Science ®Google Scholar
• Assman T, Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, doses, or indications. Clin Dermatol 2002;20(5):505-14
   PubMed Web of Science ®Google Scholar
• Murhpy LA, Atherton D. A retrospective evaluation of azathioprine in sever childhood atopic eczema, using thiopurine mehtyltransferase levels to exclude patients at hight risk of myelosuppression. Br J Dermatol 2002;147:324-30
   PubMed Web of Science ®Google Scholar
• Meggit SJ, Reynolds NJ. Azathioprine for atopic eczema. Clin Exp Dermatol 2001;26:369-75
   PubMed Web of Science ®Google Scholar
• Meggit SJ, Gray JC, Reynolds NJ. Azathoprine dosed by thiopurine methyltransferase activity for moderate-to-severe-atopic eczema: a double-blind, randomised controlled trial. Lancet 2006;367:839-46
   PubMed Web of Science ®Google Scholar
• Evans WE, Hon YY, Bomgaars L, Preponderance for thiopurine S-methyltransferase deficiency and heterozygositiy among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301
   PubMed Web of Science ®Google Scholar
• Liu HN, Wong CK. In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch Dermatol Res 1997;289:94-7
   PubMed Web of Science ®Google Scholar
• Sauer H, Hantke U, Wilmanns W. Azathioprine lymphocytotoxicity. Potentially lethal damage by its imidazole derivates. Arzneimittelforschung 1988;38:820-24
   PubMed Web of Science ®Google Scholar
• Hoffjan S, Epplen JT. The genetics of atopic eczema: recent findings and future options. J Mol Med 2005;83:682-92
   PubMed Web of Science ®Google Scholar
• Cookson WO, Ubhi B, Lawrence R, Genetic linkage of childhood atopic eczema to psoriasis susceptivilitiy loci. Nat Genet 2001;27:372-3
   PubMed Web of Science ®Google Scholar
• Bradley M, Soderhall C, Luthman H, Susceptibility loci for atopic eczema on chromosomes 3, 13, 15, 17, and 18 in a Swedish population. Hum Mol Genet 2002;11:1539-48
   PubMed Web of Science ®Google Scholar
• Haagerup A, Bjerke T, Schiotz PO, Atopic eczema– a total genome-scan for susceptibility genes. Acta Derm Venereol 2004;84:346-52
   PubMed Web of Science ®Google Scholar
• Morar N, Cookson W, Harper J, Moffat M. Filaggrin mutations in children with severe atopic eczema. J Invest Dermatol 2007;127:1667-72
   PubMed Web of Science ®Google Scholar
• Walley AJ, Chavanas S, Moffat MF, Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:175-8
   PubMed Web of Science ®Google Scholar
• Foelster-Holst R, Stoll M, Koch WA, Lack of asscociation of SPINK5 plymorphism with nonsyndromic atopic eczema in the population of Northern Germany. Br J Dermatol 2005;152:1365-7
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009;8(12):1106-11
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Zeichner JA, Eichenfield LF, MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 2008;152:854-9
   PubMed Web of Science ®Google Scholar
• Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005;15:31-6
   PubMed Web of Science ®Google Scholar
• Ring J. The therapeutic concept of patient management in atopic eczema. Allergy 1995;51:206-15
   Web of Science ®Google Scholar
• Werfel T, Breuer K, Rueff F, Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61(2):202-5
   PubMed Web of Science ®Google Scholar
• Rasche C, Heine G, Lee H, Verträglichkeit der spezifischen Immuntherapie mit Pollinex quattro bei Patienten mit atopischer Dermatitis. Allergo J 2008;17:85
   Google Scholar
• Bussmann C, Maintz L, Hart J, Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007;37(9):1277-85
   PubMed Web of Science ®Google Scholar
• Till SJ, Frances JN, Nouri-Aria IK, Durham SR. Mechanism of immunotherapy. J Allergy Clin Immunol 2004;113:1025-34
   PubMed Web of Science ®Google Scholar
• Durham SF, Varney VA, Gaga M, Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy l999;29:1490-6
   PubMed Web of Science ®Google Scholar
• Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121:288-96
   PubMed Web of Science ®Google Scholar
• Ogden Ns, Biolory L. Probiotics, a complementary approach in the treatment and prevention of pediatric atopic disease. Curr Opin Allergy Clin Immunol 2005;5(2):179-84
   PubMed Web of Science ®Google Scholar
• Arkwrite PD, David TJ. Eat dirt-the hypothesis of atopic diseases. In: David TJ, editor, Recent advances in Paediatrics 21. Royal Society of Medicine Press Ltd, London; 2004. p. 199-215
   Google Scholar
• Kalliomaki M, Salminen S, Arvillommi H, Probiotics in primary prevention of atopic disease. A randomized placebo-controlled trial. Lancet 2001;357:1076-9
   PubMed Web of Science ®Google Scholar
• Volz T, Biedermann T. Outside-in. Probiotic topical agents. Hautarzt 2009;60(10):795-801
   PubMed Web of Science ®Google Scholar
• Paul C, Lahfa M, Bachelez H, A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic eczema. Br J Dermatol 2002;147(3):518-22
   PubMed Web of Science ®Google Scholar
• Wakim M, Alazard M, Yajima A, High dose intravenous immunoglobulin in atopic eczema and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998;81(2):153-8
   PubMed Web of Science ®Google Scholar
• Jolles S, Sewell C, Webster D, Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic eczema: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003;83(6):433-7
   PubMed Web of Science ®Google Scholar
• Capella GL, Frigerio E, Altomar G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic eczema of adults. Eur J Deramtol 2001;11(3):209-13
   PubMed Web of Science ®Google Scholar
• Veien NK, Busch-Sorensen M, Stausbol-Gron B. Montelukast treatment of moderate to severe atopic eczema in adults: a randomized, double-blind, placebo controlled trial. J Am Acad Dermatol 2005;53:147-9
   PubMed Web of Science ®Google Scholar
• Bremmer MS, Bremmer SF, Baig-Lewis S, Simpson EL. Are biologics safe in the treatment of atopic eczema? A review with a focus on immediate hypersensivitiy reactions. J Am Acad Dermatol 2009;61(4):666-76
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Cox L, Platts-Mills TA, Finegold I, American College of Allergy, Asthma and Immunology, American Academy of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-7
   PubMed Web of Science ®Google Scholar
• Andres C, Belloni B, Mempel M, Ring J. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep 2008;8:179-80
   PubMed Web of Science ®Google Scholar
• Krathen RA, Hsu S. Failure of omalizumab for the treatment of severe adult atopic eczema. J Am Acad Dermatol 2005;53:338-40
   PubMed Web of Science ®Google Scholar
• Simon D, Wittwer J, Kostylina G, Alefacept (lymphocyte function associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-4
   PubMed Web of Science ®Google Scholar
• Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic eczema. J Allergy Clin Immunol 2008;122:423-4
   PubMed Web of Science ®Google Scholar
• Jacobi A, Antoni C, Manger B, Infliximab in the treatment of moderate to severe Atopic eczema. J Am Acad Dermatol 2005;53:522-8
   Web of Science ®Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063-70
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Corren J, Efficacy of soluble Il-4 receptor for the treatment of adults with asthma. J Allergy clin Immunol 2001;107:963-70
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31
   PubMed Web of Science ®Google Scholar
• Ploetz SG, Simon HU, Darsow U, Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Eng J Med 2003;349(24):2334-9
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T, Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic eczema. Allergy 2005;60:693-6
   PubMed Web of Science ®Google Scholar
• Ogbogu PU, Bochner BS, Butterfield JH, Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124:1319-1325
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Eng J Med 2008;358:1215-28
   PubMed Web of Science ®Google Scholar
• Simon D, Hösli S, Kostylina G, Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy clin Immunol 2008;121:122-8
   PubMed Web of Science ®Google Scholar
• Imai T, Nagira M, Takagi S, Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999;11:81-8
   PubMed Web of Science ®Google Scholar
• Wakugawa M, Nakamura K, Kainuma T, Tamaki K. CC chemokine receptor 4 as a possible target for therapy of atopic dermatitis. Drug News Perspect 2002;15(3):175
   PubMed Web of Science ®Google Scholar
• Tudhope SJ, Catgley MC, Fenwick PS, The role of IkappaB kinase2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells. J Immunol 2007;179(9):6237-45
   PubMed Web of Science ®Google Scholar
• Renda T, Baraldo S, Pelaia G, Increased activation of p 38 MAPK in COPD. Eur Respir J 2008;31(1):62-9
   PubMed Web of Science ®Google Scholar
• Smith SJ, Fenwick PS, Nicholson AG, Inhibitory effect of p38 MAPK kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006;149(4):393-404
   PubMed Web of Science ®Google Scholar
• Medicherla S, Fitzgerald MF, Spicer D, p38alpha-selecitve mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008;324(3):921-9
   PubMed Web of Science ®Google Scholar
• Schacke H, Hennekes H, Schottelius A, SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Research Foundation Workshop 2002;(40):375-71
   Google Scholar
• Song ICH, Gold R, Straub RH, New glucocorticoids on the horizon: repress don't activate! J Rheumatol 2005;32(7):1199-207
   Google Scholar
• Schacke H, Zollner TM, Docke WD, Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009;158(4):1088-103
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma A, IL-31: A new link between T-cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117(2):411-7
   PubMed Web of Science ®Google Scholar
• Dillon SR, Sprecher C, Hammond A, Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:572-60
   Web of Science ®Google Scholar
• Bilsborough J, Leung DY, Maurer M, IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin immunol 2006;117:418-25
   PubMed Web of Science ®Google Scholar
• Schulz F, Marenholz I, Fölster-Holst R, A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 2007;120:1097-102
   PubMed Web of Science ®Google Scholar